57 related articles for article (PubMed ID: 38436112)
21. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.
Zhang CH; Li M; Lin YP; Gao Q
Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231
[TBL] [Abstract][Full Text] [Related]
22. Hepatocellular Carcinoma Multidisciplinary Clinic-Cairo University (HMC-CU) score: A new simple score for diagnosis of HCC.
Abdelaziz AO; Nabil MM; Omran DA; Abdelmaksoud AH; Asem N; Shousha HI; Elbaz TM; Leithy R
Arab J Gastroenterol; 2020 Jun; 21(2):102-105. PubMed ID: 32439235
[TBL] [Abstract][Full Text] [Related]
23. Advanced liver imaging using MR to predict outcomes in chronic liver disease: a shift from morphology to function liver assessment.
Verde F; Romeo V; Maurea S
Quant Imaging Med Surg; 2020 Mar; 10(3):805-807. PubMed ID: 32269940
[No Abstract] [Full Text] [Related]
24. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study.
Assalino M; Terraz S; Grat M; Lai Q; Vachharajani N; Gringeri E; Bongini MA; Kulik L; Tabrizian P; Agopian V; Mehta N; Brustia R; Vitali GC; Andres A; Berney T; Mazzaferro V; Compagnon P; Majno P; Cillo U; Chapman W; Zieniewicz K; Scatton O; Toso C
Transpl Int; 2020 May; 33(5):567-575. PubMed ID: 31994238
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology and surveillance for hepatocellular carcinoma: New trends.
Singal AG; Lampertico P; Nahon P
J Hepatol; 2020 Feb; 72(2):250-261. PubMed ID: 31954490
[TBL] [Abstract][Full Text] [Related]
26. Performance of Serum Glypican 3 in Diagnosis of Hepatocellular Carcinoma: A meta-analysis.
Xu D; Su C; Sun L; Gao Y; Li Y
Ann Hepatol; 2019; 18(1):58-67. PubMed ID: 31113610
[TBL] [Abstract][Full Text] [Related]
27. Disease Burden of Hepatocellular Carcinoma: A Global Perspective.
Sayiner M; Golabi P; Younossi ZM
Dig Dis Sci; 2019 Apr; 64(4):910-917. PubMed ID: 30835028
[TBL] [Abstract][Full Text] [Related]
28. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score.
Yang JD; Addissie BD; Mara KC; Harmsen WS; Dai J; Zhang N; Wongjarupong N; Ali HM; Ali HA; Hassan FA; Lavu S; Cvinar JL; Giama NH; Moser CD; Miyabe K; Allotey LK; Algeciras-Schimnich A; Theobald JP; Ward MM; Nguyen MH; Befeler AS; Reddy KR; Schwartz M; Harnois DM; Yamada H; Srivastava S; Rinaudo JA; Gores GJ; Feng Z; Marrero JA; Roberts LR
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):531-538. PubMed ID: 30464023
[TBL] [Abstract][Full Text] [Related]
29. Soft Tissue Tumor Immunohistochemistry Update: Illustrative Examples of Diagnostic Pearls to Avoid Pitfalls.
Wei S; Henderson-Jackson E; Qian X; Bui MM
Arch Pathol Lab Med; 2017 Aug; 141(8):1072-1091. PubMed ID: 28745570
[TBL] [Abstract][Full Text] [Related]
30. A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma.
Attallah AM; El-Far M; Abdel Malak CA; Farid K; Omran MM; Yahya RS; Saad EA; Albannan MS; Attallah AA; El Basuni MA; Ali IS; Abed SB; El Naggar MA
Ann Hepatol; 2015; 14(6):869-80. PubMed ID: 26436359
[TBL] [Abstract][Full Text] [Related]
31. Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting.
Burak KW; Sherman M
Can J Gastroenterol Hepatol; 2015 May; 29(4):178-84. PubMed ID: 25965437
[TBL] [Abstract][Full Text] [Related]
32. Increased expression of CCN2, epithelial membrane antigen, and fibroblast activation protein in hepatocellular carcinoma with fibrous stroma showing aggressive behavior.
Kim GJ; Rhee H; Yoo JE; Ko JE; Lee JS; Kim H; Choi JS; Park YN
PLoS One; 2014; 9(8):e105094. PubMed ID: 25126747
[TBL] [Abstract][Full Text] [Related]
33. MUC1: a multifaceted oncoprotein with a key role in cancer progression.
Nath S; Mukherjee P
Trends Mol Med; 2014 Jun; 20(6):332-42. PubMed ID: 24667139
[TBL] [Abstract][Full Text] [Related]
34. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
;
Eur J Cancer; 2012 Mar; 48(5):599-641. PubMed ID: 22424278
[No Abstract] [Full Text] [Related]
35. Evaluation of cytokeratin-1 in the diagnosis of hepatocellular carcinoma.
Attallah AM; El-Far M; Abdel Malak CA; Zahran F; Farid K; Omran MM; Zagloul H; El-Deen MS
Clin Chim Acta; 2011 Nov; 412(23-24):2310-5. PubMed ID: 21924253
[TBL] [Abstract][Full Text] [Related]
36. Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease.
Yilmaz Y
Aliment Pharmacol Ther; 2009 Dec; 30(11-12):1103-9. PubMed ID: 19769633
[TBL] [Abstract][Full Text] [Related]
37. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis.
Yilmaz Y; Kedrah AE; Ozdogan O
World J Gastroenterol; 2009 Sep; 15(35):4387-91. PubMed ID: 19764089
[TBL] [Abstract][Full Text] [Related]
38. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
von Elm E; Altman DG; Egger M; Pocock SJ; Gøtzsche PC; Vandenbroucke JP;
Ann Intern Med; 2007 Oct; 147(8):573-7. PubMed ID: 17938396
[TBL] [Abstract][Full Text] [Related]
39. Cytokeratin markers come of age.
Linder S
Tumour Biol; 2007; 28(4):189-95. PubMed ID: 17717426
[TBL] [Abstract][Full Text] [Related]
40. Keratin profiles may differ between intraepidermal and intradermal invasive eccrine porocarcinoma.
Kurokawa I; Urakawa Y; Senba Y; Kawabata E; Nishimura K; Omoto Y; Tokime K; Mizutani H; Tsubura A
Oncol Rep; 2006 Sep; 16(3):473-7. PubMed ID: 16865245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
